Biocerta develops functional drug sensitivity testing that shows how a patient’s tumor responds to a wide range of FDA-approved cancer therapies before treatment begins. Our CertaPath platform evaluates living tumor cells ex vivo, providing direct evidence of which drugs demonstrate meaningful activity for each individual patient. This approach addresses a core limitation of genomic profiling by measuring real drug response rather than inferring it from mutations alone. Early clinical studies in AML and sarcoma show that DST-guided therapy can reveal options not typically considered and may help avoid ineffective, toxic treatments.
We are building this platform to support oncologists when treatment decisions are most uncertain, especially in relapsed or refractory disease where standard regimens often fail. Our work combines several years of laboratory development, clinical feasibility studies across
multiple cancer types, and emerging AI methods designed to predict effective drug combinations. Biocerta’s mission is to bring functional precision medicine into routine care so clinicians have clearer, evidence-driven insight into which therapies offer the greatest potential benefit for each patient.
